Starting signal sounded: analytica 2012 to offer Early Bird discount

The starting signal has sounded for analytica 2012 in Munich. Application forms for the 23rd International Trade Fair for Laboratory Technology, Analysis and Biotechnology are available to interested companies. Also, a new offer is being introduced this year: For the first time ever, companies that register by January 31, 2011 will receive a five-percent Early Bird discount on selected stand space. Stand-space allocation for analytica 2012 was also moved forward considerably, i.e. to March 15, 2011.

"Preparations for analytica 2012 are already moving ahead at full speed. New application forms are now available," explains Susanne Grödl, Exhibition Director for analytica at Messe München. "As a result, things are moving along much earlier than in previous years, and we can offer our exhibitors an additional incentive: an Early Bird discount of five percent."

The discount applies to all stand space booked between September 1, 2010 and January 31, 2011, regardless of stand size and type (corner, row or island stand). The offer that is even worthwhile for smaller stands.

"The objective of this campaign is to give exhibitors an incentive to book their stand space early," adds Grödl. "After all, earlier registration allows us to move the entire planning process including visitor advertising considerably forward in time - which is something that exhibitors ultimately profit from."

Companies that do not automatically receive their application forms for the 2012 fair can download them directly at www.analytica.de/en/2012.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...